Suzhou Hospital of Traditional Chinese Medicine
13
8
8
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
Role: collaborator
CAV Regimen for R/R AML
Role: collaborator
CAV Regimen for R/R Ph- B-ALL
Role: collaborator
Venetoclax Combined With Azactidine in the Treatment of ALAL
Role: collaborator
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
Role: collaborator
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
Role: collaborator
CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
Role: collaborator
Venetoclax Based Regimen for R/R T-ALL
Role: collaborator
Using the Chinese Indigenization FS Scale in the Diagnosis of Fibromyalgia： Specificity and Sensitivity in Clinical Practice
Role: collaborator
MG Granules Improve COVID-19 Efficacy and Safety of Convalescent Exercise Tolerance
Role: collaborator
Nutritional Management in Respiratory Critically Ill Patients -an Observational Study in Mainland China
Role: collaborator
Tong-Luo-Qu-Tong Plaster for KOA: a Randomised, Double-blind, Parallel Positive Control, Multi-center Clinical Trial
Role: collaborator
Qishe Pill for Cervical Radiculopathy
Role: collaborator
All 13 trials loaded